To the Editor: I appreciated reading the letter by Klawans et al. in the May 8 issue of the Journal regarding eight years of follow-up on the levodopa provocative test in persons at risk for Huntington's disease. I was greatly disappointed, however, that these investigators did not state unambiguously that they do not recommend this test as a routine clinical procedure. They did mention in their last sentence that no new patients are being enrolled in the provocation protocol, but this statement may not be strong enough to discourage clinicians from using this test.Readers should be aware of . . .